Edition:
United States

Inovio Pharmaceuticals Inc (INO.O)

INO.O on Nasdaq

4.64USD
21 Nov 2017
Change (% chg)

$0.08 (+1.75%)
Prev Close
$4.56
Open
$4.62
Day's High
$4.74
Day's Low
$4.58
Volume
1,074,637
Avg. Vol
1,503,017
52-wk High
$9.86
52-wk Low
$4.20

Chart for

About

Inovio Pharmaceuticals, Inc. (Inovio) is a clinical-stage pharmaceutical company, which is involved in developing deoxyribonucleic acid (DNA) immunotherapies and vaccines focused on treating and preventing cancers and infectious diseases. The Company's DNA-based immunotherapies, in combination with its electroporation delivery... (more)

Overall

Beta: 2.91
Market Cap(Mil.): $411.75
Shares Outstanding(Mil.): 90.30
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 200.64 15.49
EPS (TTM): -- -- --
ROI: -- -10.01 11.95
ROE: -- -35.77 15.94

BRIEF-Inovio pharmaceuticals reports 2017 third quarter financial results

* Inovio Pharmaceuticals reports 2017 third quarter financial results

Nov 08 2017

BRIEF-Inovio Pharma says ‍on Oct 30, Apollobio board approved agreements of license & collaboration agreement with co which was announced on July 14

* Inovio Pharmaceuticals says ‍on Oct 30, Apollobio board approved agreements of license & collaboration agreement with co which was announced on July 14

Nov 02 2017

BRIEF-Inovio Pharma initiates immuno-oncology clinical study for glioblastoma

* Inovio Pharmaceuticals initiates immuno-oncology clinical study for glioblastoma in combination with Regeneron’S PD-1 inhibitor Source text for Eikon: Further company coverage:

Nov 01 2017

BRIEF-Inovio Pharmaceuticals reports positive results from phase 1 trial of zika virus vaccine

* Inovio Pharmaceuticals Inc ‍reported on positive safety and immune response results from phase 1 trial of a vaccine against zika virus​

Oct 05 2017

BRIEF-Inovio and partners initiate Phase 1/2A clinical trial to further advance its vaccine against deadly MERS infection

* Inovio and partners initiate Phase 1/2A clinical trial to further advance its vaccine against deadly MERS infection

Sep 18 2017

BRIEF-Inovio’s cancer immunotherapy slowed PSA rise and increased PSA doubling times in patients with recurrent prostate cancer

* Inovio’s cancer immunotherapy (ino-5150) slowed PSA rise and significantly increased psa doubling times in patients with recurrent prostate cancer

Sep 11 2017

BRIEF-Inovio Pharmaceuticals reports Q2 loss per share $0.13

* Inovio Pharmaceuticals reports 2017 second quarter financial results

Aug 08 2017

BRIEF-Inovio Pharmaceuticals prices 12.5 mln share offering at $6 per share

* Inovio announces pricing of public offering of common stock

Jul 19 2017

BRIEF-Inovio Pharmaceuticals says co has about $92 mln of cash and cash equivalents and short-term investments - SEC Filing

* Inovio Pharmaceuticals Inc - As Of June 30, co has about $92.0 million of cash and cash equivalents and short-term investments - SEC Filing Source text: [http://bit.ly/2vzazOH] Further company coverage:

Jul 18 2017

BRIEF-Inovio announces proposed public offering of common stock

* Inovio Pharmaceuticals Inc - intends to offer and sell $75.0 million of shares of its common stock in an underwritten public offering

Jul 18 2017

Competitors

  Price Chg
Johnson & Johnson (JNJ.N) $138.34 +0.41
Novartis AG (NOVN.S) CHF83.55 +0.45
Pfizer Inc. (PFE.N) $35.54 +0.19
Merck & Co., Inc. (MRK.N) $54.27 +0.17
Sanofi SA (SASY.PA) €76.44 +0.69
GlaxoSmithKline plc (GSK.L) 1,303.00 -10.50
AstraZeneca plc (AZN.L) 5,036.00 +75.50

Earnings vs. Estimates